ݔѪt(y)W(xu)g(sh)ZhZձ

l(f)rg:2020-10-22 Դ: Y(ji) c

hZ ݔѪt(y)W(xu)g(sh)Zձ

ꑣ (ni)أ



_ T A

ABO blood group determination ABO ѪͶ ABO Ѫͷ ABO ѪͶ ABOѪʹ_ absorption and elution test շɢԇ ?jng)_ԇ շɢԇ ጳyԇ acute hypervolemic hemodilution; AHH ԸѪҺϡ ԸѪѪҺϡ ԸѪҺϡ ԸѪѪҺϡ acute normovolemic hemodilution; ANH ԵѪҺϡ ԵѪѪҺϡ ԵѪҺϡ ԵѪҺϡ adverse event ¼ ¼ ¼ ¹ allelic resolution typing λˮƽ o λˮƽ (yng)ˮƽ alloimmunization ͬNw w w w altruistic blood donation ԫIѪ ԾѪ ԾѪ ԾѪ antibody screening wY wYz wYz wYz apheresis blood component βѪҺɷ xg(sh)ѪҺɷ ΒѪҺɷ ɷѪѪҺɷ Apheresis β xg(sh) Β ɷݾѪ audit criteria ˜ʄt ˘˜ ˜ʄt ˜ʄt autologous transfusion wݔѪ wѪ wݔѪ Ѫ B

blood cold chain ѪҺ ѪҺ ѪҺ ѪҺ blood donation adverse reaction IѪ(yng) Ѫ(yng) Ѫ(yng) Ѫ(yng) blood donation times per thousand population ǧ˿ګIѪ˴ ÿǧ˿ھѪ˴ ǧ˿ھѪ˴ ǧ˿ھѪ˴ blood donation IѪ Ѫ Ѫ Ѫ blood donor IѪ Ѫ Ѫ Ѫ߻ʿ blood establishment computer system ѪվϢϵy(tng) ѪC(gu)YӍϵy(tng) ѪҺYӍϵy(tng) ѪXϵy(tng) blood group typing Ѫb Ѫͷ Ѫb Ѫͷ blood quality ѪҺ|(zh) ѪҺƷ|(zh) ѪҺ|(zh) ѪҺ|(zh) blood screening test ѪҺYԇ ѪҺYzԇ ѪҺYz ѪҺYzyԇ blood-borne occupational exposure ѪԴšI(y)¶ ѪҺȾԼšI(y)¶ ѪԴšI(y)¶ ѪԴšI(y)| blood-donor care IѪo Ѫo ѪP(gun)o Ѫʿo C

cell grouping cell salvage Ѫ ѪҺ Ѫ clinical transfusion medicine RݔѪW(xu) RݔѪt(y)W(xu) RݔѪt(y)W(xu) RݔѪt(y)W(xu) closed system ]ϵy(tng) ]ϵy(tng) ]ϵy(tng) ܷϵy(tng) compatibility test ԇ ԇ ԙz Ԝyԇ complement-dependent lymphocytotoxicity test; CDC awهԼԇ awهܰ򶾚ԇ awهԼԇ awهܰͼ(yng)yԇ complication related to blood donation IѪP(gun)l(f)Y ѪP(gun)l(f)Y ѪP(gun)l(f)Y ѪP(gun)l(f)Y confirmatory test _Cԇ _Jԇ _Cz _Jyԇ copper sulfate method ~ ~ ~ ~yԇ corrected count increment; CCI ѪСӋ(sh)Уֵ ѪСӋ(sh)УӔ(sh) ݔעѪСָ(sh) Уָ(sh) crossmatch Ѫ Ѫ Ѫ Ѫ D

department of transfusion medicine t(y)ԺݔѪ ݔѪt(y)W(xu) t(y)ԺݔѪ o diversion pouch ·D(zhun)ƴ ӱռ ӱռ donor (informed) consent IѪ֪ͬ Ѫ֪ͬ Ѫ֪ͬ Ѫʿ@֪ͬ donor deferral IѪ ѪѪ Ѫ Ѫ donor identification IѪߴ_J Ѫ˴_J Ѫݴ_J Ѫʿݴ_J donor quarantine IѪ Ѫ˸x o Ѫʿx donor reentry IѪߚw Ѫپ ѪپѪ ѪʿپѪ donor IѪ Ѫ Ѫ Ѫ E

electronic crossmatch ӽѪ ӽѪ ӽѪ XѪ elite controller Ӣ Ӣ o o emerging infection °l(f)Ⱦ °l(f)Ⱦ °l(f)Ⱦ °l(f)Ⱦ event ¼ ¼ ¼ ¼¹ external quality assessment; EQA g|(zh)ur ⲿƷ|(zh)u ⲿ|(zh)ur |(zh)u F

febrile non-hemolytic transfusion reaction; FNHTR Ѫ԰l(f)ᷴ(yng) Ѫ԰l(f)(yng) Ѫ԰l(f)ᷴ(yng) Ѫ԰l(f)(yng) first-time donor ΫIѪ ξѪ ״ξѪ ξѪ߻״ξѪ

forward type o freezing ك ٱ fundamental

transfusion

medicine A(ch)ݔѪW(xu) A(ch)ݔѪt(y)W(xu) A(ch)ݔѪt(y)W(xu) A(ch)ݔѪt(y)W(xu) G

grey zone ҅^(q) o ҅^(q) ɫ؎ H

haemovigilance; HV ѪҺȫO(jin)y ѪҺȫO(jin)y ѪҺA(y)ϵy(tng) ѪҺȫA(y)ϵy(tng) hematocrit; Hct t Ѫ t o hematology analyzer method ѪҺxzy ѪҺxzy ѪҺxzy ѪҺx Hemoglobin; Hb Ѫt Ѫt Ѫt ѪtػѪt hemoglobin test strip colorimetric assay Ѫtԇlɫ Ѫtԇlɫ Ѫtԇlɫ o high resolution typing ߷ֱʷ ߽ȷ ߷ֱʷ ߽ histocompatibility matching M M䌦 M M human leucocyte antigen; HLA ׼ԭ Ѫԭ ׼ԭ Ѫԭ I

immediate hemolytic transfusion reaction; IHTR ٰl(f)ѪݔѪ(yng) l(f)ѪݔѪ(yng) ѪݔѪ(yng) ѪݔѪ(yng) incidence rate ¸Ⱦ l(f) ¸Ⱦ l(f) initial test ԇ ԇ Ιz yԇ inter-instrument comparison xgȌ xgȌ xgȌ x֮g^ inter-laboratory comparison gȌ gȌ gȌ ֮g^ internal audit (ni)|(zh) (ni) (ni)|(zh) (ni) internal quality control; IQC ҃(ni)|(zh) ҃(ni)Ʒ (ni)|(zh) (ni)Ʒ|(zh) inter-reagent comparison ԇȌ ԇȌ ԇȌ ԇ֮g^ inter-regional donor quarantine ^(q)“(lin) o o o inventory management ѪҺ ѪҺ irradiation ݗ

ݗ(չ)

ݗ ݗ L

laboratory information management system Ϣϵy(tng) YӍϵy(tng) YӍϵy(tng) YӍϵy(tng)

leukocyte reduction ȥ׼ p ȥ׼ ȥѪѪ Look back low resolution typing ͷֱʷ ͽȶ ͷֱʷ o lymphocyte microcytotoxicity test; LCT ΢ܰͼԇ ΢ܰ򶾚ԇ ΢ܰͼԇ o M

major crossmatch (c)Ѫ 󽻲 (c)Ѫ ҪѪ management review u 팏 u u minor crossmatch ΂(c)Ѫ С ΂(c)Ѫ ҪѪ mixed lymphocyte culture; MLC ܰͼB(yng) ܰB(yng) ܰͼB(yng) o mixed lymphocyte reaction; MLR ܰͼ(yng) ܰϷ(yng) ܰͼ(yng) o N

natural antibody Ȼw Ȼw Ȼw Ȼw naturally occurring antibody Ȼw Ȼa(chn)w Ȼa(chn)Ŀw Ȼa(chn)w near miss ¼ Eeʧ Uʧ¼ o non-reactive o(yng) o(yng) o(yng) o(yng) non-remunerated voluntary blood donor ԸoIѪ oѪ oѪ oѪ nucleic acid testing yield; NAT yield zy z o yԇ O

occult HBV infection; OBI [͸ײȾ [ B ͸ײȾ [͸ײȾ [͸ one-way mixed lymphocyte culture ܰͼB(yng) ܰB(yng) ܰͼB(yng) o P

panel cells V M V o panel reactive antibody; PRA wV(yng) Mw(yng) wV(yng) o para-Bombay phenotype I IѪ I o pathogen inactivation; PI ԭw ԭ ԭw ԭ pathogen reduction; PR ԭwȥ ԭp ԭwȥ ԭ patient blood management; PBM ѪҺ ѪҺ ѪҺ Ѫ plasma exchange Ѫ{ÓQ Ѫ{ÓQ Ѫ{ÓQ QѪ{ platelet count; PLT ѪСӋ(sh) ѪСӋ(sh) ѪСӋ(sh) ѪС唵(sh)

platelet-rich plasma method ѪСѪ{ ѪСѪ{ ѪСѪ{ preoperative autologous blood donation; PAD g(sh)ǰwѪ g(sh)ǰwѪ g(sh)ǰwѪ g(sh)ǰѪ pretransfusion testing ݔѪǰzy ݔѪǰz ݔѪǰz ݔѪǰz prevalence rate ʢ proficiency testing; PT C ԇ C yԇ Q

quality objective |(zh)Ŀ Ʒ|(zh)Ŀ |(zh)Ŀ |(zh)Ŀ quality assurance |(zh)C Ʒ|(zh)C |(zh)C |(zh)^ quality control |(zh) Ʒ|(zh) |(zh) |(zh) R

reactive (yng) (yng) (yng) (yng) recalcification of plasma Ѫ{(f)} Ѫ{} Ѫ{(f)} Ѫ{} recipient (informed) consent Ѫ֪ͬ Ѫ֪ͬ Ѫ֪ͬ Ѫ߫@֪ͬ recipient identification Ѫߴ_J Ѫߴ_J Ѫݴ_J Ѫݴ_J red cell group system tѪϵy(tng) tѪѪϵy(tng) tѪϵy(tng) tѪϵy(tng) red cell reagent panel ԇtM tѪԇM ԇtM o regular donor ګIѪ ھѪ Ҏ(gu)Ѫ aѪ߻ھѪ repeat donor ؏(f)IѪ }Ѫ }Ѫ }Ѫ residual risk L(fng)U NL(fng)U NL(fng)U NL(fng)U reverse type o RhD initial typing RhD Ѫͳz RhD z RhD Ѫͳz RhD z RhD typing RhD Ѫb RhD RhD Ѫb RhD Ѫ͙z confirmatory test

for

Rh

negative Rh Դ_J

Rh Դ_J

Rh Դ_J Rh Դ_Jyԇ risk behavior L(fng)UО L(fng)UО ΣО L(fng)UΣО S

science of blood donation service IѪ(w)W(xu) Ѫ(w)W(xu) Ѫ(w)W(xu) Ѫ(w)ƌW(xu) seroconversion ѪD(zhun)Q ѪD(zhun) ѪD(zhun) ѪD(zhun)Q serum grouping Ѫ嶨 Ѫ Ѫ嶨 o shelf life ڻЧ solid phase HLA antibody detection HLA wYxg(sh) HLA wzyg(sh) HLA wYxo

technology g(sh) standard operation procedure; SOP ˜ʲҎ(gu) ˜ʲ ˜ʲ ˜ʲ sterile welding o۽ o۽ o۽ o T

therapeutic apheresis ίԆβ ίԷxg(sh) ίԆΒ o therapeutic dose ί ί ί o traceability of blood component ѪҺɷֿ׷ۙ ѪҺɷ֮׷ ѪҺɷֿ׷ ׷ۙѪҺɷ transfusion complications ݔѪl(f)Y ݔѪl(f)Y ݔѪl(f)Y ݔѪa(chn)F(xin)āl(f)Y transfusion management ݔѪW(xu) ݔѪ ݔѪ ݔѪ transfusion reactions ݔѪ(yng) ݔѪ(yng) ݔѪ(yng) ݔѪa(chn)F(xin)ķ(yng) transfusion technology ݔѪg(sh)W(xu) ݔѪg(sh) ݔѪg(sh)W(xu) ݔѪg(sh) transfusion-associated circulation overload; TACO ݔѪP(gun)ѭh(hun)ؓ ݔѪP(gun)ѭh(hun)d ݔѪP(gun)ѭh(hun)ؓ o transfusion-free medicine oݔѪt(y)W(xu) ݔѪt(y) ݔѪt(y)W(xu) ݔѪt(y)W(xu) transfusion-transmissible infection ɽ(jng)ݔѪĸȾ ɽ(jng)ݔѪĸȾ ɽ(jng)ݔѪĸȾ ͸^ݔѪȾĂȾ transfusion-transmitted bacterial infection; TTBI ݔѪļȾ ݔѪļȾ (jng)ݔѪļȾ ͸^ݔѪȾļȾ transfusion-transmitted infection; TTI ݔѪȾ ݔѪĸȾ (jng)ݔѪȾ ͸^ݔѪȾĂȾ U

unexpected antibody identification ⿹wb Ҏ(gu)t(A(y))wYz twwa o unexpected antibody screening ⿹wY Ҏ(gu)t(A(y))wYz twwYz o V

validation of blood establishment computer system ѪվϢϵy(tng)_J ѪC(gu)YӍϵy(tng)C ѪҺYӍϵy(tng)_J ѪҺXϵy(tng)Ч_J validation _J C _J Ч_J W

window period մ մ մ

P(gun)~hZ ݔѪ g(sh)Z

cx

(qun) ѹӢժ m.serialtips.com
谁有黄色毛片黄色网站,天天操美女的逼干,美女131湿影院,完美伴侣电视剧